Duragesic pediatric exclusivity ruling
Executive Summary
FDA decision prohibiting Mylan from launching its Duragesic generic until J&J's pediatric exclusivity expires was upheld by D.C. appeals court Nov. 30. Court says agency did not err in converting Mylan's ANDA approval from "final" to "tentative," and in treating the company's Paragraph IV certification as a Paragraph II, after a Vermont court ruled that Mylan's fentanyl patch infringed J&J's patent. Duragesic's pediatric exclusivity expires Jan. 23 (1"The Pink Sheet" Aug. 23, 2004, p. 15)...
You may also be interested in...
Concerta generics in 2005?
Johnson & Johnson's guidance for earnings per share in 2005 - released in conjunction with the Guidant acquisition - assumes that there will be generic competition for both the transdermal fentanyl patch Duragesic and the methylphenidate formulation Concerta, the company told analysts Dec. 16. Mylan expects to launch a generic version of Duragesic Jan. 23, when J&J's pediatric exclusivity expires (1"The Pink Sheet" Dec. 6, 2004, In Brief). Andrx' ANDA for a generic version of Concerta has been held up by a petition filed by J&J in March, arguing that the agency should apply stricter bioequivalence standards to the product...
FDA Decision On Mylan Duragesic ANDA Upheld By D.C. Court
FDA did not err in barring Mylan's transdermal fentanyl patch from coming to market until after Johnson & Johnson/Alza's pediatric exclusivity for Duragesic expires Jan. 23, a D.C. federal court said
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.